|
Airline Partner
 |
Scientific Program
Thursday, September 4, 2014
17:00-19:30 |
STEM CELL THERAPY IN NEUROLOGY (Hall A) |
|
Chairpersons
|
Dani Offen, Israel
Lawrence S. Goldstein, USA |
|
16:30-17:00 |
Greetings
|
|
17:00-17:30 |
The context: History, state of the art of stem cell therapy
Dani Offen, Israel
|
|
17:30-18:00 |
Stem cells and neurotherapeutics: More than cell therapy
Oliver Bruestle, Germany
|
|
18:00-18:30 |
Stimulating brain plasticity and neurological recovery by cell-based therapy
Michael Chopp, USA |
|
18:30-19:00 |
The future is not yet here
Lawrence S. Goldstein, USA
|
|
19:00-19:30
|
Panel-audience Discussion - Where do we go from here?
|
|
19:30-20:30 |
Networking Reception |
Friday, September 5, 2014
08:30-09:15 |
INDUSTRY SPONSORED SESSION |
09:30-12:30 |
DISEASE MODIFYING DRUGS FOR MULTIPLE SCLEROSIS (Hall A) |
|
Chairpersons
|
Ludwig Kappos, Switzerland
Douglas L. Arnold, Canada
|
|
09:30-10:00
|
Update: Current compounds in phase III clinical trials
Tobias Derfuss, Switzerland
|
|
10:00-10:30
|
Dilemma: What is to be considered 'treatment failure' in MS management?
Nicola De Stefano, Italy |
|
10:30-11:00
|
Coffee Break
|
|
11:00-12:30
|
Debate: The end points in MS disease evaluations
|
|
Discussion
|
|
09:30-12:30
|
STROKE THERAPY: CURRENT DILEMMAS (Hall B)
|
|
Chairpersons |
Louis R. Caplan, USA
Michael Brainin, Austria
|
|
09:30-10:00
|
New certainties create new uncertainties: Recent stroke trials
Michael Brainin, Austria
|
|
10:00-10:30
|
Dilemma: Treatment of carotid stenosis: When and how?
Leo Bonati, Switzerland
|
|
10:30-11:00
|
Coffee Break
|
|
11:00-11:30
|
Treatment of extracarnial and intracarnial dissections: Are there guidelines?
Stephanie Debette, France
|
|
11:30-12:00
|
PFO: How to choose the best treatment?
Jonathan Streifler, Israel |
|
12:00-12:30
|
Should we use perfusion imaging in therpay choices?
Franz Faszekas, Austria |
|
12:30-14:00
|
INDUSTRY SPONSORED SESSION |
|
14:00-15:00
|
Lunch Break |
15:00-17:30 |
MORE STIMULATION FOR THE BRAIN? (Hall A) |
|
Chairpersons |
Marwan Hariz, UK
Walter Paulus, Germany |
|
15:00-15:30 |
Unusual targets for DBS in patients with PD and Parkinsonian syndromes
Marwan Hariz, UK
|
|
15:30-16:00 |
Electromagnetic brain stimulation in neurotherapy
Abraham Zangen, Israel
|
|
16:00-16:30 |
Coffee Break
|
|
16:30-17:00 |
Brain stimulation in rehabilitation
Walter Paulus, Germany
|
|
17:00-17:30 |
Intracranial stimulation for epilepsy
Paul Boon, Belgium
|
15:00-17:30 |
PRACTICAL THERAPY IN NEUROLOGY (Hall B) |
|
Chairpersons |
Zohar Argov, Israel
|
|
15:00-15:30 |
Treating myasthenia without evidence
Zohar Argov, Israel
|
|
15:30-16:00 |
Restless leg syndrome: Scope of therapy and its complications
Mauro Manconi, Switzerland
|
|
16:00-16:30 |
Coffee Break
|
|
16:30-17:30 |
Free communication - Oral presentation and discussion:
|
|
17:45-18:30
|
Special Lecture:
Placebo effect and the brain
Fabrizio Benedetti, Italy
|
Saturday, September 6, 2014
08:30-11:00 |
MANAGEMENT DILEMMAS IN MULTIPLE SCLEROSIS (Hall A) |
|
Chairpersons
|
Nicola De Stefano, Italy
Nancy Richert, USA |
|
08:30-09:00
|
Risk assessment and monitoring strategies for MS therapies
David Leppert, Switzerland |
|
09:00-09:30
|
How should we monitor patients for development of PML?
Nancy D. Richert, USA |
|
09:30-10:00
|
Pediatric MS: How different is it?
Brenda L. Banwell, USA |
|
10:00-10:30
|
Coffee Break
|
|
10:30-11:00
|
Debate: Life risking' therapy in MS: Where should we draw a line?
|
|
Discussion
|
08:30-11:00 |
EPILEPSY THERAPY: OLD DILEMMAS AND PROMISING FUTURE (Hall B) |
|
Chairpersons
|
Hannah Cock, UK
Sam Berkovic, Australia
|
|
08:30-09:00 |
New anti-epileptic medications |
|
09:00-09:30 |
Will exome sequencing affect the therapy of epilepsy?
Sam Berkovic, Australia |
|
09:30-10:00 |
Anti inflammatory drugs in epilepsy: Does it impact Epileptogenesis?
Annamaria Vezzani, Italy |
|
10:00-10:30
|
Coffee Break
|
|
10:30-11:00 |
Dilemma: When to stop drugs in 'non active' epileptic patient
Tony Marson, UK |
| 11:00-12:30 |
Free Communications - Abstract Presentation Moderator: Israel Steiner, Israel
|
| 12:30-14:00 |
Lunch Break |
14:00-17:30 |
THE FUTURE OF NEUROTHERAPEUTICS (Hall A) |
|
Chairperson |
Robert H. Brown, UK
Paul M. Matthews, UK
|
|
14:00-14:30
|
The hurdles of future drug development in neurology
Joseph Berger, USA
|
|
14:30-15:00
|
Personalized medicine: Can we tailor individual therapy for patients?
Paul M. Matthews, UK
|
|
15:00-15:30
|
ALS: Should we be dependent on experimental animal models?
Robert H. Brown, USA |
|
15:30-16:00
|
Coffee Break
|
|
16:00-16:30
|
Stroke: Imaging on the way to the hospital- is it worth the expense?
Louis R. Caplan, USA |
|
16:30-17:00
|
What is the future of head-to-head clinical trials in MS?
John Richert, USA |
|
17:00-17:30
|
Future therapies in inherited myopathies
Robert C. Griggs, USA
|
|
17:45-18:30
|
SPECIAL LECTURE:
Medical marijuana in neurological therapy
Arthur G. Lipman, USA
|
Sunday, September 7, 2014
09:00-11:30 |
THE ETHICS OF HUMAN NEUROTHERAPY (Hall A) |
|
Chairperson |
Anjan Chatterjee, USA
|
|
09:00-09:30
|
Ethical issues in ALS treatment
Robert H. Brown, USA
|
|
09:30-10:00
|
The continued search for a coherent language of benefit of AD treatment
Jason Karlawish, USA
|
|
10:30-11:00
|
Ethical Dilemma 2: Should we prescribe cognitive enchancement drugs to normal people?
Anjan Chaterjee, USA
|
|
11:00-11:30
|
IRB: The history and the context
Meir Lahav, Israel
|
09:00-11:30 |
GENDER NEUROLOGY: SHOULD WE BE MORE ATTENTIVE? (Hall B) |
|
Chairpersons
|
Bettina Schmitz, Germany
|
|
09:00-09:30
|
How much should sex be a factor in clinical trials?
Meir Steiner, Canada |
|
09:30-10:00
|
Epilepsy: Pharmacological consideration during pregnancy
Bettina Schmitz, Germany |
|
10:00-10:30
|
Pregnancy in MS: How to maintain therapy and avoid risk
Sandra Vukusic, France |
|
10:30-11:00
|
Stroke therapy in pregnancy: What should we worry about?
Barbara Tettenborn, Switzeland |
|
11:30-12:00
|
Summary and closure
|